Evidence map›Paper›PMID 31238892›Full record

ArticleBMC cancer2019

Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.

Naohiko Nakamura, Etsuro Hatano, Kohta Iguchi, Motohiko Sato, Hiroaki Kawaguchi, Iwao Ohtsu, Takaki Sakurai, Nobuhiro Aizawa, Hiroko Iijima, Shuhei Nishiguchi and 7 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Article
  3. Oxidised Apolipoprotein Peptidome Characterises Metabolic Dysfunction-Associated Steatotic Liver Disease.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 1 country.

Naohiko NakamuraDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Etsuro HatanoDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan. shatano@hyo-med.ac.jp.
Kohta IguchiDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Motohiko SatoDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hiroaki KawaguchiDepartment of Hygiene and Health Promotion Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Iwao OhtsuDepartment of Headquarters for International Industry-University Collaboration, Tsukuba University, Ibaragi, Japan.
Takaki SakuraiDepartment of Diagnostic Pathology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Nobuhiro AizawaDivision of Hepatobiliary and Pancreatic Diseases, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan.
Hiroko IijimaDivision of Hepatobiliary and Pancreatic Diseases, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan.
Shuhei NishiguchiDivision of Hepatobiliary and Pancreatic Diseases, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan.
Takuya TomonoDepartment of Life and Medical Systems, Faculty of Life and Medical Sciences, Doshisha University, Kyoto, Japan.
Yukihiro OkudaDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Seidai WadaDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Satoru SeoDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kojiro TauraDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Shinji UemotoDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Masaya IkegawaDepartment of Life and Medical Systems, Faculty of Life and Medical Sciences, Doshisha University, Kyoto, Japan. mikegawa@mail.doshisha.ac.jp.
Kyoto University · JPHyogo Medical University · JPDoshisha University · JPKagoshima University · JPTsukuba International University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNoninvasive biomarkers are urgently needed for optimal management of nonalcoholic fatty liver disease (NAFLD) for the prevention of disease progression into nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). In order to identify the biomarkers, we generated the swine hepatocellular carcinoma (HCC) model associated with NAFLD and performed serum proteomics on the model.

methodsMicrominipigs were fed a high-fat diet to induce NAFLD and a normal diet as the control. To induce HCC, diethylnitrosamine was intraperitoneally administered. Biopsied liver samples were histopathologically analyzed every 12 weeks. Serum proteins were separated by blue native two-dimensional gel electrophoresis and proteins of interest were subsequently identified by MALDI-TOF MS/MS. Human serum samples were analyzed to validate the candidate protein using antibody-mediated characterization.

resultsIn the NAFLD pigs, hepatic histology of nonalcoholic steatohepatitis (NASH) was observed at 36 weeks, and HCC developed at 60 weeks. Among serum proteins identified with MALDI-TOF MS/MS, serum inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4), an acute response protein which is secreted primarily by liver, was identified as the most characteristic protein corresponding with NAFLD progression and HCC development in the NAFLD pigs. With immunoassay, serum ITIH4 levels in the NAFLD pigs were chronologically increased in comparison with those in control animal. Furthermore, immunohistochemistry showed ITIH4 expression in hepatocytes also increased in both the cancer lesions and parenchyma as NAFLD progressed. Human study is also consistent with this observation because serum ITIH4 levels were significantly higher in HCC-NAFLD patients than in the simple steatosis, NASH, and virus-related HCC patients. Of note, HCC-NAFLD patients who had higher serum ITIH4 levels exhibited poorer prognosis after hepatectomy.

conclusionsWe established an HCC pig model associated with NAFLD. Serum proteomics on the swine HCC with NAFLD model implicated ITIH4 as a non-invasive biomarker reflecting NAFLD progression as well as subsequent HCC development. Most importantly, the results in the swine study have been validated in human cohort studies. Dissecting speciation of serum ITIH4 promises to have clinical utility in monitoring the disease.

Indexed as

Acute-Phase ProteinsAdolescentAdultAgedAnimalsBiomarkersBlood ProteinsCarcinogensCarcinoma, HepatocellularDiet, High-FatDiethylnitrosamineDisease Models, AnimalDisease ProgressionFemaleGlycoproteinsHepatectomyAcute-Phase ProteinsBiomarkersBlood ProteinsCarcinogensDiethylnitrosamineGlycoproteinsITIH4 protein, humanITIH4 protein, Sus scrofaProteinase Inhibitory Proteins, SecretoryBlue native/SDS gel electrophoresisHepatocellular carcinomaInter-alpha-trypsin inhibitor heavy chain 4MALDI-TOF MS/MSNonalcoholic fatty liver diseasePig model

Identifiers

PMID31238892
PMCPMC6591942
OpenAlexW2954918590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.